Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study

Abstract

Licence for PublicationThe Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BJO and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence (http://bjo.bmj.com/ifora/licence.pdf).Competing Interest: None declared. BRVO) were enrolled in the study. Three intravitreal injections of 1 mg bevacizumab (0.04 ml) were administered at 4 week intervals; further retreatment was based on optical coherence tomography (OCT) findings. Follow-up examinations were done at days 1, 7 and 28 and at monthly intervals thereafter. Results: Mean baseline central retinal thickness (CRT) in OCT was 558 µm (range 353 to 928 µm) and mean BCVA was 20/100. One day after the first injection, CRT significantly decreased to 401 µm (p < 0.01). Three injections reduced macular edema to 328 µm CRT (p < 0

Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion

“…The side effects in terms of an elevation in intraocular pressure were present in the triamcinolone group only, in a similar frequency and amount as already reported for Caucasians and in another study on Chinese patients. [21][22][23][24][25] The finding of a discrepancy between a recurrence of macular oedema and continuously improved visual acuity agrees with an observation by Kriechbaum et al, 32 in which 3 months after the injection macular oedema recurred and visual acuity remained unchanged.…”

“…6,7,[9][10][11][12][13][14][15][16][17][18][19] The two major side effects of the intravitreal triamcinolone were a steroid induced increase in intraocular pressure and development of cataract. [21][22][23][24][25] In contrast, studies on intravitreal bevacizumab by Rosenfeld et al and other researchers showed an improvement in visual acuity, reduction in macular thickness, and only minor complications in patients with CRVOs, [26][27][28][29][30][31][32][33][34] so that intravitreal triamcinolone was rapidly exchanged by intravitreal bevacizumab for the treatment of CRVO. It agrees with this study, in which the best-corrected visual acuity improved significantly in the triamcinolone group and in the bevacizumab group with a no statistically significant difference in the gain in visual acuity between both study groups, although the reduction in macular oedema was slightly more pronounced in the triamcinolone group (Table 2) (Figure 1).…”

“…In study by Kriechbaum et al, 32 three initial injections were administered at 4-week intervals, 32 although the intervals in other studies were usually 6 weeks to 2 months. 34 In the investigation by Hsu et al, 29 Iturralde et al, 27 and in our study, only one initial injection was primarily given.…”

A clinical study to evaluate the efficacy of intravitreal Anti-VEGF therapy in treating macular edema due to retinal venous occlusions

“…8 Kreichbaum et al have reported a decrease of central macular thickness from 558 m at baseline to 382 m at 6 months with 3, one monthly injection. 9 In our study we found a decrease in central macular thickness from a mean of 586.30 m at baseline to a mean of 329.10 m at approximately 12e16 weeks, i.e. after the third Anti-VEGF injection, which was again statistically significant ( p < 0.0001).…”

“…Kreutzer et al 8 reported improvement in visual acuity from 0.79 (0.39) log MAR to 0.51 (0.34) log MAR at 6 months ( p ¼ 0.009). Kreichbaum et al 9 reported an increase in BCVA from a mean of 20/100 at baseline to 20/50 at 6 months. In our study we observed an improvement in best corrected visual acuity from a mean of log MAR þ1.084 at baseline (Snellen's equivalent ¼ 5/60 approximately) to a mean of log MAR þ0.455 (Snellen's equivalent ¼ 6/18).…”